Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Syros Pharmaceuticals Inc (SYRS)

Syros Pharmaceuticals Inc (SYRS)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
0.0300 -0.0004 (-1.32%) 03/28/25 [OTC US]
N/A x N/A N/A x N/A
Post-market 0.0300 unch (unch) 15:59 ET
Quote Overview for Fri, Mar 28th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.0253
Day High
0.0304
Open 0.0267
Previous Close 0.0304 0.0304
Volume 640,500 640,500
Avg Vol N/A N/A
Stochastic %K N/A N/A
Weighted Alpha N/A N/A
5-Day Change -0.0315 (-51.22%) -0.0315 (-51.22%)
52-Week Range 0.0215 - 0.1000 0.0215 - 0.1000
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure

Fundamentals

See More
  • Market Capitalization, $K 1,650
  • Shares Outstanding, K 26,832
  • Annual Sales, $ 9,940 K
  • Annual Income, $ -164,570 K
  • EBIT $ -112 M
  • EBITDA $ -109 M
  • 60-Month Beta 1.31
  • Price/Sales 11.17
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.36
  • Most Recent Earnings $-0.68 on 10/31/24
  • Next Earnings Date 03/26/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -1.19
  • Growth Rate Est. (year over year) +84,049.58%

Most Recent Stories

More News
S&P Futures Tick Higher Ahead of Key U.S. PPI Data, Home Depot Earnings on Tap

September S&P 500 E-Mini futures (ESU24) are trending up +0.11% this morning as investors awaited crucial U.S. producer inflation data, comments from a Federal Reserve official, and an earnings report...

ESU24 : 5,699.99s (-0.31%)
KEY : 15.61 (-1.20%)
MNDY : 239.00 (-3.24%)
SBUX : 96.95 (-0.80%)
RILY : 4.10 (+2.50%)
HD : 354.97 (-0.89%)
TECN.Z.EB : 167.500 (-3.68%)
FNOX.S.DX : 86.600 (+32.54%)
CXAI : 0.8700 (+5.97%)
SYRS : 0.0300 (-1.32%)
RUM : 6.92 (-4.42%)
DELL : 90.00 (-2.48%)
Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host...

SYRS : 0.0300 (-1.32%)
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted...

SYRS : 0.0300 (-1.32%)
Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for...

SYRS : 0.0300 (-1.32%)
Syros to Participate in Upcoming Investor Conferences in March

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive...

SYRS : 0.0300 (-1.32%)
Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host...

SYRS : 0.0300 (-1.32%)
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted...

SYRS : 0.0300 (-1.32%)
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the United...

SYRS : 0.0300 (-1.32%)
Syros Announces Clinical Updates and 2023 Strategic Priorities

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in advancing new standards of care for the frontline treatment of hematologic malignancies, today provided an update on its clinical development programs and...

SYRS : 0.0300 (-1.32%)
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 14,200...

SYRS : 0.0300 (-1.32%)

Business Summary

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company's product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients...

See More

Key Turning Points

3rd Resistance Point 0.0369
2nd Resistance Point 0.0337
1st Resistance Point 0.0318
Last Price 0.0300
1st Support Level 0.0267
2nd Support Level 0.0235
3rd Support Level 0.0216

See More

52-Week High 0.1000
Fibonacci 61.8% 0.0700
Fibonacci 50% 0.0608
Fibonacci 38.2% 0.0515
Last Price 0.0300
52-Week Low 0.0215

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies